drugset / Trial / NCT05732064

Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality

NCT05732064

Phase 4 Completed 180 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Breast cancer patients often have sleep disturbances during the perioperative period. Dexmedetomidine is a highly selective alpha 2-adrenoceptor agonist with sedative, anxiolytic, and analgesic effects. Previous studies showed that night-time low-dose dexmedetomidine infusion improved sleep quality. Esketamine is a N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and analgesic. Recent studies showed that low-dose esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that low-dose dexmedetomidine-esketamine combined nasal administration at night can improve perioperative sleep quality in patients scheduled for breast cancer surgery.

Timeline

Start
2023-05-22
Primary completion
2025-04-20
Completion
2025-07-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Intranasal
Subject Esketamine Other / unclassified 0.2 mg/kg Intranasal